- Home
- NEGG vs CMPS Comparison
NEGG vs CMPS Comparison
Compare NEGG & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | CMPS |
|---|---|---|
| Founded | 2001 | 2020 |
| Country | United States | United Kingdom |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.9M | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEGG | CMPS |
|---|---|---|
| Price | $15.37 | $11.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.38 |
| AVG Volume (30 Days) | 49.3K | ★ 4.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $3.92 |
| 52 Week High | $137.84 | $15.40 |
Technical Indicators
Market Signals| Indicator | NEGG | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.35 |
| Support Level | N/A | $11.14 |
| Resistance Level | N/A | $14.92 |
| Average True Range (ATR) | 0.00 | 0.95 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 0.00 | 10.90 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.